2023 World Conference on Lung Cancer (Posters)-EP08.02. Induction Immunochemotherapy Before Definitive Chemoradiotherapy for Unresectable Locally Advanced Non-small Cell Lung Cancer

EP08.02. Induction Immunochemotherapy Before Definitive Chemoradiotherapy for Unresectable Locally Advanced Non-small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to evaluate the effectiveness and safety of using induction immune checkpoint inhibitors (ICIs) and chemotherapy followed by definitive chemoradiotherapy (CRT) for patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). The study included patients who received neoadjuvant immunochemotherapy followed by CRT between 2019 and 2022. The primary endpoints were overall survival (OS) and progression-free survival (PFS), while secondary endpoints included disease control rate (DCR) and toxicities.<br /><br />The results showed that the disease control rate after induction immunochemotherapy was 87.3%. The median PFS was 20.4 months, with PFS rates of 90.1% at 6 months, 70.4% at 1 year, 55.2% at 18 months, and 41.9% at 2 years. The overall survival rates were 92.8% and 76.2% at 1 and 2 years, respectively, and the median OS was not reached. Patients who did not experience progression before CRT had a median PFS of 21.3 months. <br /><br />Furthermore, concurrent chemoradiotherapy (cCRT) showed significantly better overall survival compared to sequential chemoradiotherapy (sCRT). Patients with PD-L1 expression of 50% or more had a significantly higher partial response rate and better survival compared to those with lower PD-L1 expression.<br /><br />The treatment was well tolerated, with a low incidence of grade 3 or greater pneumonitis or radiation pneumonitis. The most common severe adverse events were hematologic toxicities, and no unexpected treatment-related toxicities occurred.<br /><br />In conclusion, induction immunochemotherapy followed by definitive CRT shows promising efficacy and tolerable toxicities for patients with unresectable LA-NSCLC, particularly those with tumoral PD-L1 expression over 50%. This treatment approach could be a viable option for these patients.

Asset Subtitle

Leilei Wu

Meta Tag

Speaker Leilei Wu

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

study

induction immune checkpoint inhibitors

chemotherapy

chemoradiotherapy

non-small cell lung cancer

overall survival

progression-free survival

disease control rate

PD-L1 expression

toxicities